%0 Journal Article %T Hepatocellular Carcinoma Post Direct Anti Hepatitis C Viral Agents; Clinical Features %J African Journal of Gastroenterology and Hepatology %I Scientific Society of Kafr El-Sheikh Doctors %Z 2735-5489 %A Ahmed, Nabila H %A Elwan, Amira %A Abdelrahman, Essam Adel %A Embaby, Ahmed %A Mohammed, Ahmed S %D 2022 %\ 12/18/2022 %V 5 %N 2 %P 5-15 %! Hepatocellular Carcinoma Post Direct Anti Hepatitis C Viral Agents; Clinical Features %K Liver cirrhosis %K HCV %K direct antiviral drugs %K Hepatocellular carcinoma %K Focal lesion %R 10.21608/ajgh.2022.177155.1021 %X Background:Direct Anti Hepatitis C Viral Agents (DAAs) were introduced for Hepatitis C Virus (HCV) infection management, which resulted in high sustained virological response (SVR) in many countries and a low failure rate. However, hepatocellular carcinoma (HCC) post DAAs therapy is controversial; few studies related aggressive pattern HCC to DAAs. Therefore, we aimed to study the hepatocellular carcinoma relation to direct anti-hepatitis C viral drugs.Patients and Methods: This observational case-control study included 67 adults Egyptian HCC patients associated with HCV diagnosed at the Zagazig University Hospitals, who were divided into two groups according to DAAs treatment.Results: HCC is more common in male patients (77.6%) of all studied cases, and those are treated by DAAs (62.7%). The median age of HCC post-DAA was 63(48-83), while 58 (45-75) in HCC patients without DAA, with no significant difference p= 0.053. HCC presented in the non-DAAs treated group, mainly decompensating by hematemesis (HM) (32%). While in the post-DAAs group, HCC was significantly diagnosed primarily with abdominal pain at 31%. There is no significant difference as regards the liver status with frequent liver cirrhosis in both groups, 14(56%) and 32(76.2%). Conclusion: DAAs therapy of HCV added no additional risk for hepatocellular carcinoma. %U https://ajgh.journals.ekb.eg/article_274751_864d8cec036cc20496268a5689b3397c.pdf